How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?

The Use of Iron Supplementation to Reduce ESA Dosing in Hemodialysis

Authors


Address correspondence to: Steven Fishbane, MD, 100 Community Dr, 2nd Floor, Great Neck, NY 11021, Tel.: +516-465-8200, or e-mail: Sfishbane@NSHS.edu.

No abstract is available for this article.

Ancillary